New clinical trial on myelofibrosis at the Clinique de Genolier
The Clinique de Genolier is the first site in Switzerland to launch a new clinical trial in the field of myelofibrosis.
The «Manifest-3» trial, sponsored by Novartis and led by Dr Rebmann as Principal Investigator, focuses on evaluating a new treatment option for patients with this condition. It aims to expand treatment options in a context where medical needs remain significant.
This launch marks a significant milestone in the development of clinical research within the Swiss Medical Network. It demonstrates the commitment of the teams at the Clinique de Genolier to advancing therapeutic approaches and actively contributing to medical progress.
Clinical research plays a vital role within our network. It enables us to offer innovative solutions within a structured framework, for the benefit of patients and healthcare professionals.
